SPO Medical Unveils New Oximetry Devices in the US Market

Products to be launched at AARC International Respiratory Congress in Orlando,Florida

NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- SPO Medical Inc.

(OTC Bulletin Board: SPOM), a leading developer of biosensor andmicroprocessor technologies for use in portable monitoring devices, will bedemonstrating its new PulseOx 6000(TM) and PulseOx 6100(TM) in the US marketat the 53rd Annual International Respiratory Congress of the AmericanAssociation for Respiratory Care (AARC) in Orlando, Florida (December 1-3,2007).

The PulseOx 6000(TM) (finger device) and PulseOx 6100(TM) (hand-helddevice) have both been designed for use by medical professionals, hospitalsand managed care facilities. Both the PulseOx 6000(TM) and PulseOx 6100(TM)use patented Reflective Pulse Oximetry (RPO) technology for accurate andreliable measurements of blood oxygen saturation and heart rate, and includethe SPO Medical new AutoSpot(TM) technology for patients suffering lowperfusion. Both products have regulatory clearance for marketing in the UnitedStates and are planned to become commercially available in the first quarterof 2008.

"We are delighted to introduce the PulseOx 6000(TM) and PulseOx 6100(TM)for the first time in the US at AARC's International Respiratory Congress, themost prestigious gathering of respiratory care professionals," said MichaelBraunold, President and Chief Executive Officer of SPO Medical. "Our businessstrategy and product achievements to date are a testament to our continuedsuccess in delivering new life-saving and life-enhancing products to therespiratory marketplace."

AARC, a professional membership association of respiratory therapists,focuses primarily on respiratory therapy education and research. Its goals areto ensure that respiratory patients receive safe and effective care fromqualified professionals and to benefit respiratory health care providers.AARC's International Respiratory Congress is a one-stop destination for thelatest scientific evidence on the care and treatment of respiratory conditionsand the newest and most advanced respiratory technology.

SPO Medical will be located at booth #237 and their executives will beavailable to answer questions at the AARC International Respiratory Congress.

About SPO Medical:

SPO Medical (SPOM) a leading developer of biosensor and microprocessortechnologies for use in portable monitoring devices to capture life-saving andlife-enhancing information within four key markets: medical care; home andremote-care; sports and wellness; and safety and security. Its patentedtechnology uses information gathered from the reflectance of light on thehuman blood stream, in a non-invasive manner, to monitor key vital signs. TheCompany distributes its products through a network of distributors and alsolicenses its technologies to appropriate client corporations forcommercialization and distribution. For more information, visitwww.spomedical.com.

Safe Harbor:

This press release contains forward-looking statements that involvesubstantial uncertainties and risks. These forward-looking statements arebased upon our current expectations, estimates and projections about ourbusiness and our industry, and that reflect our beliefs and assumptions basedupon information available to us at the date of this release. We cautionreaders that forward-looking statements are predictions based on our currentexpectations about future events. These forward-looking statements are notguarantees of future performance and are subject to risks, uncertainties andassumptions that are difficult to predict. Our actual results, performance orachievements could differ materially from those expressed or implied by theforward-looking statements as a result of a number of factors, including butnot limited to, changes in economic conditions generally and the medicaldevices market specifically, changes in technology, legislative or regulatorychanges that affect us, the availability of working capital, changes in costsand the availability of goods and services, the introduction of competingproducts, planned product launches, changes in our operating strategy ordevelopment plans, our ability to attract and retain qualified personnel, andthe risks and uncertainties discussed under the heading "Risk Factors" in Item1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31,2006. We undertake no obligation to revise or update any forward-lookingstatement for any reason.SOURCE SPO Medical Inc.Michael Braunold, CEO of SPO Medical Inc., 011-972-9-7643570,info@spomedical.com; or Christine J. Petraglia of Seventh Circle Consultingfor SPO Medical Inc., +1-646-354-8886, investors@spomedical.com